Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

NCT01489969 | Completed Phase 2 Results

• 1 other identifier: Neu-P11-03-PSG
• Study Type: interventional
• Target: 137
• Locations: 1 country
• Sites: 9

Brief Summary

This is a phase II study. It is conducted using a randomized, double-blind, 3-arm placebo controlled, parallel group design. Eligible patients will be randomized in a 1:1:1 ratio to receive Neu-P11 20 mg, Neu-P11 50 mg or placebo for 4 weeks The objective of this study is to assess the efficacy of Neu-P11 (20 and 50mg) on sleep continuity parameters in insomnia patients aged 18-80 years, following the first two nights (immediate effect) and at the end of 4 weeks of double-blind treatment. The primary efficacy endpoint in this study is Latency to Persistent Sleep (LPS) measured by polysomnogram (PSG) at the first two nights of treatment (nights 15-16 of the study; mean of two consecutive nights recordings). The secondary endpoints are number of awakenings after sleep onset and the duration of wake after sleep onset measured by PSG at the first two nights of treatment (nights 15-16 of the study; mean of two consecutive nights recordings).

Conditions

Primary Insomnia

Keywords

sleep latency; Sleep maintenance; Sleep fragmentation; Polysomnography

Outcome Measures

Primary Outcomes (1)

• Latency to Persistent Sleep

  The primary efficacy parameter is Latency to persistent sleep (LPS) measured by the PSG at the first two nights (immediate effect) of the double blind treatment period. LPS was summarized at baseline and after two days double-blind treatment (actual and change from baseline) for each treatment group using descriptive statistics. For each treatment group, the mean score at the end of the two days was compared, adjusting for the baselinescore. An ANCOVA model was used. Lower score indicates reduction in latency to persistent sleep and thus considered improvement

  2 days

Other Outcomes (2)

• Number of Awakenings (NOA)

  28 days

• Duration of Wake After Sleep Onset (WASO)

  28 days

Study Arms (3)

20 mg

ACTIVE COMPARATOR

Neu-P11 dose of 20 mg

Drug: Neu-P11

50 mg

ACTIVE COMPARATOR

Neu-P11 dose of 50 mg

Drug: Neu-P11

placebo

PLACEBO COMPARATOR

matching placebo

Drug: Neu-P11

Interventions

Neu-P11 DRUG

1 tablet daily 1-2 before bed time for 28 days of double blind treatment

Also known as: Melatonin agonist

20 mg; 50 mg; placebo

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female and aged 18-80 years (both ages included).
• Suffering from primary insomnia according to DSM-IV criteria (307.42 primary insomnia, Appendix 25.1) (based on a Sleep History Questionnaire (SHQ) that is given to the patient at Visit Day 0, Appendix 25.1).
• Reported subjective sleep latency of at least 30 minutes on at least three nights per week for at least one month and subjective WASO of at least 45 minutes per night on at least 3 nights per week for at least one month (based on the SHQ).
• Subjects with habitual bed time within the range of 21:00-01:00 (inclusive), as reported by the subject during screening on Day 0.
• If female of childbearing potential, using a reliable method of contraception during the entire study duration and for at least 3 months after study drug intake.
• Have not been using benzodiazepine (BZD) and non-BZD hypnotics or melatoninergic drugs for the past 2 weeks or more prior to Screening.
• Have not been using psychotropic treatments for the past 3 months or more prior to Screening.
• Are stabilized on non-psychotropic treatments for more than 3 months prior to Screening.
• Are willing to sign a written informed consent to participate in the study.
• After initial screening, recruited patients will enter a 2 week placebo baseline/eligibility period.
• Patients will be admitted into a sleep lab and will continue to the double blind treatment phase if polysomnography (PSG) results meet the following criteria:
• Mean LPS ≥30 minutes on both PSG screening nights, with neither night \<15 minutes.
• Mean total sleep time (TST) ≤390 minutes, or mean WASO ≥30 minutes on both of the 2 PSG screening nights, with neither night \<15 minutes.

You may not qualify if:

• According to DSM IV, subjects belonging to the following groups are excluded: 780.59 (breathing related sleep disorder); 307.45 (circadian rhythm sleep disorder); 307.47 (dyssomnia not otherwise specified); 780.xx (sleep disorder due to general medical condition)
• Subjects suffering from insomnia secondary to other causes according to the sleep history questionnaire.
• Use of psychotropic treatments for the past 3 months and during the study.
• Use of strong CYP inhibitors in the preceding 3 months and during the study
• Use of benzodiazepines or other hypnotics during preceding two weeks (including all benzodiazepines; zopiclone, zolpidem, zaleplon, barbiturates, buspirone and hydroxyzine).
• Alcohol intake - no more than 2 alcoholic drinks per day and any consumption less than 2 hours before study drug intake.
• Immunosuppressive medication in the preceding 3 months and during the study
• Severe neurological, psychiatric disorders especially psychosis, anxiety and depression
• Intercurrent acute or chronic somatic diseases likely to interact with sleep (for example: chronic pain from any etiology, benign prostatic hypertrophy likely to require surgery in the coming six months)

Sponsors & Collaborators

• Neurim Pharmaceuticals Ltd.: lead

Study Sites (9)

Pacific Research Network

San Diego, California, 92103, United States

Location

MD Clinical

Hallandale, Florida, 33009, United States

Location

Miami research Associates

South Miami, Florida, 33143, United States

Location

Sleep Disorders Centers of Georgia

Atlanta, Georgia, 30342, United States

Location

Chicago Research Center

Chicago, Illinois, 60634, United States

Location

Vince & Associates Clinical Research

Overland Park, Kansas, 66212, United States

Location

Community Research and Sleep Management

Crestview Hills, Kentucky, 41017, United States

Location

Center for Sleep and Wake Disorders

Chevy Chase, Maryland, 20815, United States

Location

Clinilabs, Inc.

New York, New York, 10119, United States

Location

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders; Sleep Deprivation

Interventions

N-(2-(5-methoxy-indol-3-yl)-ethyl)-4-oxo-4H-pyran-2-carboxamide

Condition Hierarchy (Ancestors)

Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Amnon Katz
• Organization: Neurim Pharmaceuticals (1991) LTD

amnonk@neurim.com

972-3-768-4906

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 6, 2011
• First Posted: December 12, 2011
• Study Start: December 1, 2011
• Primary Completion: May 1, 2012
• Study Completion: January 1, 2013
• Last Updated: June 6, 2018
• Results First Posted: June 6, 2018

Record last verified: 2018-05

Locations

US (9)